- BioCryst Pharmaceuticals ( NASDAQ: BCRX ) is scheduled to announce Q4 earnings results on Tuesday, February 21st, before market open.
- The consensus EPS Estimate is -$0.20 (+50.0% Y/Y) and the consensus Revenue Estimate is $74.18M (+57.2% Y/Y).
- Over the last 1 year, BCRX has beaten EPS estimates 25% of the time and has beaten revenue estimates 50% of the time.
- Over the last 3 months, EPS estimates have seen 2 upward revisions and 3 downward. Revenue estimates have seen 1 upward revision and 6 downward.
For further details see:
BioCryst Pharmaceuticals Q4 2022 Earnings Preview